Pharmacokinetics of total thyroxine after repeated oral administration of levothyroxine solution and its clinical efficacy in hypothyroid dogs.

Background: Oral levothyroxine (l-T4 ) supplementation is commonly used to treat hypothyroid dogs.

Objectives: Investigate the plasma profile and pharmacokinetics of total thyroxine (tT4 ) after PO administration of a l-T4 solution and its clinical efficacy in hypothyroid dogs.

Animals: Ten dogs with naturally occurring hypothyroidism.

Clinical efficacy and safety of a once-daily formulation of carbimazole in cats with hyperthyroidism.

Objective: Evaluation of efficacy and safety of a novel controlled-release formulation of carbimazole in feline hyperthyroidism.

Methods: A multicentre, self-controlled study in 44 client-owned cats with history and clinical signs of hyperthyroidism, and total thyroxine concentration greater than or equal to 50 nmol/l. Treatment was started at 15 mg once daily, response assessed after 10 days, and 3, 5, 8, 26 and 53 weeks and dose adjusted as required.

Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets.

Long-term oral treatment with cimetidine is recommended to reduce vomiting in dogs with chronic gastritis. Despite this, few studies have specifically examined the plasma disposition and pharmacokinetics of cimetidine in dogs, particularly following repeated oral administration. The pharmacokinetics of cimetidine following oral administration as tablets was investigated in healthy dogs.

Clinical evaluation of a novel liquid formulation of L-thyroxine for once daily treatment of dogs with hypothyroidism.

Background: A liquid solution of levothyroxine (L-T4) is available for treatment of canine hypothyroidism.

Hypothesis: Once daily oral administration of a liquid L-T4 solution is effective and safe for controlling hypothyroidism in dogs.

Animals: Thirty-five dogs with naturally occurring hypothyroidism.

Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.

The pharmacokinetics of ramipril and its active metabolite, ramiprilat, was determined in cats following single and repeated oral doses of ramipril (Vasotop tablets) (once daily for 9 days) at dose rates of 0.125, 0.25, 0.